Outcomes of Left Ventricular Assist Device for Patients with Hypertrophic Cardiomyopathy

There were no significant differences between the two groups about patient's baseline characteristics. HCM group had significant smaller left ventricle (LV) than DCM group. [LV end-diastolic diameter: 67 (IQR: 55-71) vs 72 (IQR: 62-82), p<0.05] In short-term outcome, there was no significant difference about in-hospital mortality. [HCM vs DCM; 2 (7%) vs 4 (4%), p=0.47] Regarding postoperative complication, HCM group required more frequent right ventricular assist device (RVAD) support than DCM group. [8 (28%) vs 4 (4%), p<0.01] In long-term outcome, the overall survival rate at 1 and 3 years was 89% and 74% in HCM group, 92% and 90% in DCM group, respectively (p=0.03). (Figure A) During the follow up period, HCM group had significantly more LVAD pump exchanges than DCM group. [hazard ratio, 4.10 95% confidence interval, 1.67 to 10.1; p=0.002] (Figure B) CONCLUSION: The long-term outcome of LVAD therapy for patients with HCM is still challenging. In particular, careful attention is required for right heart function.